AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
-6.32%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.88B
AUM Growth
+$2.88B
(-25%)
Cap. Flow
-$344M
Cap. Flow
% of AUM
-11.96%
Top 10 Holdings %
Top 10 Hldgs %
76.21%
Holding
111
New
12
Increased
16
Reduced
18
Closed
9
Top Buys
| 1 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$69.8M |
| 2 |
Amicus Therapeutics
FOLD
|
$13.3M |
| 3 |
Alibaba
BABA
|
$10.7M |
| 4 |
NIO
NIO
|
$10.5M |
| 5 |
AnaptysBio
ANAB
|
$9.98M |
Top Sells
| 1 |
WW
WW International
WW
|
$432M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$15.6M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$12.9M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$9.04M |
| 5 |
Immunic
IMUX
|
$6.85M |
Sector Composition
| 1 | Healthcare | 61.03% |
| 2 | Consumer Discretionary | 37.81% |
| 3 | Technology | 0.32% |
| 4 | Financials | 0% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
argenx
ARGX
$43.6B
| $14M | 0.37% | 185,000 +35,000 | +23% | +$2.65M |
|
|
MDCO
27
DELISTED
Medicines Co
MDCO
| $12M | 0.31% | 400,000 | – | – |
|
|
AXDX
28
DELISTED
Accelerate Diagnostics
AXDX
| $11.5M | 0.3% | 500,000 | – | – |
|
29
Regenxbio
RGNX
$451M
| $11.3M | 0.29% | 150,000 | – | – |
|
30
Denali Therapeutics
DNLI
$2.23B
| $10.9M | 0.28% | 500,000 | – | – |
|
|
31
Alibaba
BABA
$322B
| $10.7M | 0.28% | +65,000 | New | +$10.7M |
|
32
Madrigal Pharmaceuticals
MDGL
$9.76B
| $10.7M | 0.28% | 50,000 | – | – |
|
33
Solid Biosciences
SLDB
$427M
| $10.6M | 0.28% | 225,000 -25,000 | -10% | -$1.18M |
|
|
34
NIO
NIO
$14.3B
| $10.5M | 0.27% | +1,500,000 | New | +$10.5M |
|
|
BOLD
35
DELISTED
Audentes Therapeutics, Inc
BOLD
| $9.9M | 0.26% | 250,000 +14,000 | +6% | +$554K |
|
36
Rocket Pharmaceuticals
RCKT
$354M
| $9.85M | 0.26% | 400,000 | – | – |
|
37
Larimar Therapeutics
LRMR
$310M
| $9.35M | 0.24% | 800,000 -400,000 | -33% | -$4.68M |
|
|
CBAY
38
DELISTED
Cymabay Therapeutics
CBAY
| $8.86M | 0.23% | 800,000 | – | – |
|
39
Cartesian Therapeutics
RNAC
$261M
| $8.73M | 0.23% | 561,540 +61,540 | +12% | +$957K |
|
40
Iovance Biotherapeutics
IOVA
$807M
| $7.88M | 0.2% | 700,000 | – | – |
|
|
CMTA
41
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $7.72M | 0.2% | 692,000 +492,000 | +246% | +$5.49M |
|
42
Adicet Bio
ACET
$59.9M
| $7.57M | 0.2% | 500,000 -50,000 | -9% | -$757K |
|
43
Replimune Group
REPL
$422M
| $7.25M | 0.19% | +450,000 | New | +$7.25M |
|
|
STML
44
DELISTED
Stemline Therapeutics, Inc.
STML
| $6.64M | 0.17% | 400,000 | – | – |
|
|
DRNA
45
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $6.49M | 0.17% | 425,000 | – | – |
|
46
Spero Therapeutics
SPRO
$116M
| $6.31M | 0.16% | 600,000 +250,000 | +71% | +$2.63M |
|
|
YI
47
111 Inc
YI
$55.7M
| $6.08M | 0.16% | +450,000 | New | +$6.08M |
|
48
AC Immune
ACIU
$205M
| $6M | 0.16% | 750,000 +150,000 | +25% | +$1.2M |
|
|
TBIO
49
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $6M | 0.16% | 600,000 +100,000 | +20% | +$1M |
|
|
AGEN
50
Agenus
AGEN
$133M
| $5.89M | 0.15% | 2,750,000 | – | – |
|